Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 9/20 | 1.00 |
| ▸ | SYK | P43405 | 8/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 2/20 | 1.00 |
| ▸ | IGF1R | P08069 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15390767 | 0.91 | AURKA (0.82) | AURKASYKGSK3AGSK3BJAK2 | |
| SCHEMBL657530 | 0.90 | AURKA (0.82) | AURKASYKGSK3AGSK3BJAK2 | |
| SCHEMBL10187853 | 0.88 | AURKA (0.79) | AURKASYKGSK3AGSK3BJAK2 | |
| SCHEMBL25469677 | 0.88 | AURKA (0.78) | AURKASYKGSK3AGSK3BJAK2 | |
| SCHEMBL30981222 | 0.87 | GSK3B (1.00) | AURKASYKGSK3AGSK3BJAK2 | |
| SCHEMBL30072334 | 0.87 | SYK (0.76) | AURKASYKGSK3AGSK3BJAK2 | |
| SCHEMBL4276330 | 0.87 | SYK (0.76) | AURKASYKGSK3AGSK3BJAK2 | |
| SCHEMBL28080961 | 0.87 | AURKA (0.76) | AURKASYKGSK3AGSK3BJAK2 | |
| SCHEMBL657529 | 0.86 | SYK (0.75) | AURKASYKGSK3AGSK3BJAK2 | |
| SCHEMBL656765 | 0.86 | AURKA (1.00) | AURKASYKGSK3AGSK3BJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4658477-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| US-20080039622-A1 | Inhibiting the immunoglobulin (Ig) IgE and/or IgG receptor using R940343, N4-[(2,2-Difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; treating allergic and inflammatory diseases; syk kinase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | claimed |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| US-20070293520-A1 | One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| US-20070293521-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| US-20070293522-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| US-20070293523-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | claimed |
| US-20060058292-A1 | N4-[2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; inhibit the immunoglobulins IgE or IgG receptor signaling cascades in mast, basophil cells; antiallergen, antiinflammatory agent; asthma, osteoarthritis | MIDCAP FINANCIAL TRUST | 2006-03-16 | — | — | US | claimed |
| EP-1471915-A4 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2006-02-15 | — | — | EP | claimed |
| JP-2005516046-A | — | — | 2005-06-02 | — | — | JP | claimed |
| EP-1471915-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | claimed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | claimed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | claimed |
| US-20250276997-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250163028-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2025-05-22 | — | — | US | disclosed |
| US-20250144226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2025-05-08 | — | — | US | disclosed |
| WO-2004014382-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058292-A1 | N4-[2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; inhibit the immunoglobulins IgE or IgG receptor signaling cascades in mast, basophil cells; antiallergen, antiinflammatory agent; asthma, osteoarthritis | FCER2, FCGR1A, HRH4 | AURKA 533/4885SYK 36/4885GSK3A 2354/4885 |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | AURKA 997/4885SYK 54/4885GSK3A 2114/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | AURKA 1221/4885SYK 251/4885GSK3A 2239/4885 |
| US-20080039622-A1 | Inhibiting the immunoglobulin (Ig) IgE and/or IgG receptor using R940343, N4-[(2,2-Difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; treating allergic and inflammatory diseases; syk kinase inhibitors | FCER2, FCGR1A, FCGR2A | AURKA 240/4885SYK 4/4885GSK3A 1869/4885 |
| US-20070293523-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | FCER2, SYK, FCGR1A | AURKA 962/4885SYK 2/4885GSK3A 988/4885 |
| US-20250276997-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2, ATXN2L, ATXN10 | AURKA 2873/4885SYK 4862/4885GSK3A 3758/4885 |
| US-20250144226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CLN6, CACYBP, CREBBP | AURKA 4733/4885SYK 4824/4885GSK3A 2857/4885 |
| US-20070293522-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | AURKA 997/4885SYK 54/4885GSK3A 2114/4885 |
| US-20070293520-A1 | One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine | HRH4, FCER2, HRH2 | AURKA 581/4885SYK 78/4885GSK3A 3185/4885 |
| US-20070293521-A1 | inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents | FCER2, SYK, FCGR1A | AURKA 962/4885SYK 2/4885GSK3A 988/4885 |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | SYK, FCER2, FCGR1A | AURKA 485/4885SYK 1/4885GSK3A 805/4885 |
| US-20250163028-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | UBQLN2, NEDD4, UBTF | AURKA 3982/4885SYK 4800/4885GSK3A 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.